Tango Therapeutics (TNGX) EBIAT (2020 - 2025)
Tango Therapeutics (TNGX) has 6 years of EBIAT data on record, last reported at -$38.7 million in Q4 2025.
- For Q4 2025, EBIAT fell 2.86% year-over-year to -$38.7 million; the TTM value through Dec 2025 reached -$101.6 million, up 22.03%, while the annual FY2025 figure was -$101.6 million, 22.03% up from the prior year.
- EBIAT reached -$38.7 million in Q4 2025 per TNGX's latest filing, down from $15.9 million in the prior quarter.
- Across five years, EBIAT topped out at $15.9 million in Q3 2025 and bottomed at -$39.9 million in Q1 2025.
- Average EBIAT over 5 years is -$25.0 million, with a median of -$26.8 million recorded in 2023.
- Peak YoY movement for EBIAT: crashed 951806.78% in 2021, then soared 154.46% in 2025.
- A 5-year view of EBIAT shows it stood at -$22.0 million in 2021, then tumbled by 31.82% to -$29.1 million in 2022, then fell by 5.86% to -$30.8 million in 2023, then dropped by 22.45% to -$37.7 million in 2024, then dropped by 2.86% to -$38.7 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$38.7 million in Q4 2025, $15.9 million in Q3 2025, and -$38.9 million in Q2 2025.